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In palliative care (PC), the term ‘end of life’ (EoL) is
commonly used but inconsistently defined.1 This European
Society for Medical Oncology (ESMO) Clinical Practice
Guideline (CPG) refers to EoL as care for people with
advanced disease once they have reached a point of rapid
physical decline, typically the last few weeks or months
before an inevitable death as a natural result of a disease.
This guideline will only consider the last weeks and days of
life for the adult patient with advanced cancer.
At EoL, the goal of care is focused towards comfort, of-
fering a tailored and individualised management of quality
of life (QoL) and approaching death of the patient. Thus,
early integration of supportive care and PC in oncology is
essential.2 Comfort care is holistic and person-centred,
focusing on the interrelationship between physical, psy-
chosocial and spiritual issues (Figure 1). This warrants the
cessation of cancer-modifying treatments and dispropor-
tionate interventions, focusing on symptom relief and
‘whole person’ or ‘total care’. It is well documented that PC
teams improve symptom control, satisfaction and psycho-
logical support for patients and families in hospitals, hos-
pices and community settings, particularly at EoL.3 In the
absence of multiprofessional PC teams, and to enhance
better collaboration, oncologists need skills to intervene
beyond oncological therapies. Communication with the
patient and their family becomes a priority to ascertain theondence to: ESMO Guidelines Committee, ESMO Head Office, Via
6900 Lugano, Switzerland
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- Issue 4 - 2021therapeutic choices available. Furthermore, the care setting
at EoL needs careful evaluation so that monitoring of
overall well-being enables the best QoL and a dignified
death. EoL provides specific challenges in clinical manage-
ment of oncology patients, which can be addressed through
a multiprofessional and collaborative approach. Oncologists
have a responsibility to ensure the smooth transition of the
patient and family from living to dying and to coordinate
the necessary resources for effective and timely
intervention.
COMMUNICATION AND THE FAMILY
‘Family’, as understood by the patient, is the unit of care at
EoL. Identifying key people in the patient’s life is vital.
Patients, families and carers rate effective communica-
tion and shared decision making as having primary impor-
tance, ahead of other EoL domains such as expert,
respectful and compassionate care and trust and confidence
in clinicians.4 Moreover, patients often express a preference
for involving family and friends in EoL discussions.5 An
anticipatory approach, assessing patient level of knowledge
of their diagnosis, wishes around disclosure and acknowl-
edging emotional responses, is essential.6 Some patients
may choose not to confront their own mortality, or lack
capacity to do so.
The treating physician should engage in discussion about
approaching EoL, treatment options and goals of care, place
of care and place of death, and address legal or personal
matters. The potential for patients to die in their preferred
location is increased if oncologists are aware of their
preference.7
Tailored information should be shared in clear, manage-
able and jargon-free language to avoid misinterpretation, in
a location that ensures privacy. Professional interpretationhttps://doi.org/10.1016/j.esmoop.2021.100225 1
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Figure 1. Total care of the adult cancer patient at the end of life.
Turquoise: combination of treatments or other systemic treatments; white: other aspects of management.
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ESMO Open G. B. Crawford et al.services should be used if families do not share a common
language with the clinician.6,8
Patient and family understanding should always be
confirmed. Pacing and staging of information-sharing,
aligned with stage of illness or deterioration and para-
phrasing of the patient’s own words, are important
communication strategies.9 Question prompt lists may
assist relatives to overcome barriers and encourage
involvement in decision making.9 Advance care planning
with the patient can identify substitute decision makers, or
prepare family members for death, a possible protective
factor against later distress.10 Identifying relevant cultural
customs, spiritual beliefs and practices around death and
dying is equally important, as is access to spiritual care and/
or faith representatives.11
The family’s and carer’s needs for support and information
should be assessed separately from those of the patient and
referral for intervention to other experts within the multi-
disciplinary team should be considered. High levels of pre-
death distress and low levels of preparedness for death are2 https://doi.org/10.1016/j.esmoop.2021.100225associated with adverse bereavement outcomes, in addition
to spousal status, pre-death depressive symptoms, low
educational level and economic disadvantage.12,13
A family meeting or conference can explore under-
standing of prognosis and assess preparedness for death. It
may also benefit family carers by identifying and addressing
unmet needs and concerns.Patients who are parents of young children
Parents/guardians need clear prognostic information as well
as support and guidance from professionals in order to
prepare children for the death of their parent, although
professionals may be reluctant to engage because of con-
cerns about lack of time and of expertise.14,15 Parental
death during childhood is associated with increased mor-
tality in early adulthood from all causes. The ability of the
surviving parent to support and nurture healthy emotional
expression of grief by children is the most significant pro-
tective factor in limiting negative outcomes.16 AppropriateVolume 6 - Issue 4 - 2021
G. B. Crawford et al. ESMO Opensupport and advice about communicating with children
should be offered before and after death to include, where
possible, family, friends and social networks, trying to
maintain structures and routines for the children.14
Recommendations
 Effective communication and shared decision making are
essential at EoL [II, A].
 Strategic preparation of patient and family, respecting
personal wishes and beliefs, is critical to reducing
adverse bereavement outcomes [III, A].
NURSING CONSIDERATIONS
Nurses provide a critical role in the management of patients
and families in palliative and EoL care. One qualitative
systematic review proposed that nurses act as coordinators
of care by virtue of the range of nursing activities required
in PC, proximity to the patient and response to need.17,18
Core nursing roles include managing physical deteriora-
tion of the body (managing tissue viability and oral, bowel
and bladder care), guiding and supporting families in the
adjustment to the process of dying, recognition of death
and managing the moment of death and its aftermath. So
far, however, evidence is largely based on qualitative data
and/or expert opinion, particularly in relation to nursing
roles in managing patient care and comfort.19 One recent
study demonstrates the importance of nurses’ recognition
in predicting early signs of physical deterioration.17 Nurses
also have a role in addressing family burden and, given the
proximity to patient and family, advising on changing goals
and settings of care. The ability to appropriately diagnose
dying is critical to sensitively guide family members from
the point of deterioration to death.
Nurses need specific education about knowledge and at-
titudes to work in EoL care. The impact of education on
improving nursing care is demonstrated through the End-of-
Life Nursing Education Consortium (ELNEC) core curriculum,
a cascade method to extend nursing knowledge at EoL.20
Attitudes of oncology and PC nurses towards dying would
appear to be an indicator of confidence in care.21 Strategies
to embed and integrate the principles of palliative and EoL
care into nursing practice, and their benefits to multi-
professional caregiving and family support, are recognised.22
Recommendations
 The nursing role is considered vital to the care of pa-
tients and families at EoL [V, C].
 The role of PC teams is critical to the care of patients and
families at EoL [II, A].PROGNOSTIC FACTORS IN ADVANCED CANCER
Prognostic estimates may elicit important patient goals or
unfinished business and preferences about site and style of
EoL care.
Physician prediction of survival is inaccurate and often overly
optimistic. Probabilistic estimates aremore accurate. ObjectiveVolume 6 - Issue 4 - 2021factors associated with short prognosis include deteriorating
performance status (PS) and presence of symptoms including
dyspnoea, dysphagia, xerostomia, anorexia and cognitive
impairment.23 Laboratory findings associated with systemic
inflammatory response, e.g. elevated C-reactive protein (CRP)
levels, reduced albumin levels and leucocytosis, are also asso-
ciated with poor prognosis.24
Prognostic models incorporating physician prediction of
survival and clinical and laboratory factors improve the
accuracy of clinical prediction.25 Validated, most frequently-
studied tools able to predict survival are: the Palliative
Performance Scale, the Palliative Prognostic Score, the
Palliative Prognostic Index and the Glasgow Prognostic
Score. Of these, the Glasgow Prognostic Score is considered
the most favourable as it uses only two objective parame-
ters (CRP levels and decreased albumin concentration) and
has prognostic value complementary to PS.25Diagnosis of dying
Advanced cancer patients demonstrate signs predictive of
the last weeks and days of life.26 Early signs, present >1
week before death, may include reduced conscious state,
Palliative Performance Scale 20% (i.e. bed-bound,
completely dependent, food intake minimal-to-none) and
dysphagia for liquids. Late signs increasing likelihood of
death within 3 days include non-reactive pupils, pulseless-
ness of the radial artery, urine output <100 ml in 12 hours,
inability to close eyelids, Cheyne-Stokes respiration and
vocal fold grunting.23,26 A prognostic model utilising PS and
drooping of nasolabial folds has been developed; when
both are present, 3-day mortality is 94%.23 Unfortunately,
although these indicators are highly suggestive of short
prognosis, their absence does not rule out the possibility of
impending death.Recommendations
 Clinicians need to be watchful for objective physical
symptoms indicating prognosis of days to weeks, espe
cially declining PS [I, A].
 Poor prognosis is associated with declining PS and onset/
worsening of symptoms such as dyspnoea, dysphagia,
weight loss, xerostomia, anorexia and cognitive impair-
ment [I, A].
 Routine use of prognostic tools may improve accuracy of
physician predictions [III, B].RATIONALISING TREATMENTS
Discontinuation of treatments must be individualised and
influenced by patient and family preferences, goals of care,
patient prognosis and riskebenefit assessment of the
treating physician.Anticancer therapies
Chemotherapy (ChT) in the last month of life is associated
with adverse outcomes including poor quality of care,https://doi.org/10.1016/j.esmoop.2021.100225 3
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resuscitation, mechanical ventilation and with dying in an
intensive care unit.27 Radiotherapy (RT) offers limited
benefit for patients with poor PS [e.g. European Coopera-
tive Oncology Group (ECOG) grade 4] and is not recom-
mended in the last month of life.28,29 Single-fraction RT may
provide effective symptomatic relief for metastatic bone
pain within 2 weeks, or tumour-related bleeding within
2 days.30 Use of immunotherapy at EoL is associated with
increased risk of dying in hospital and potential for signifi-
cant financial hardship.31 Immune checkpoint inhibitors
should not be used at the EoL.32
Recommendations
 ChT and immunotherapy should not be used in the last
weeks of life [IV, D].
 RT may have symptomatic benefit for pain or bleeding
but is not recommended in the last days of life [III, D].
ROUTES OF DRUG ADMINISTRATION
As death approaches, the oral route may be unsuitable due
to generalised weakness, swallowing dysfunction, altered
consciousness, nausea, vomiting or bowel obstruction.
Intermittent or continuous administration of medication
either intravenously (i.v.) or subcutaneously (s.c.) is effec-
tive, taking into account opioid and other medication dose
conversion ratios from the oral route.33 Gastrostomy or
nasogastric tubes should not be initiated, but if in situ may
be of benefit. If the gastrostomy tube is dislodged, or the i.v.
central access is lost, reinsertion may be inappropriate.
Placement of s.c. access and transdermal patches on the
trunk or abdomen may ensure more effective absorption
and distribution of medication. Transdermal delivery sys-
tems (e.g. fentanyl or buprenorphine patches) may be
continued but initiation or increase in dose of transdermal
treatment is not recommended because efficacy may be
unpredictable due to decreasing peripheral perfusion,
sweating or acute absorption from fever, causing adverse
effects.
The preferred route of administration for most patients is
continuous s.c. infusion, considered safe, flexible, broadly
feasible and non-burdensome. Leaving an s.c. cannula in
situ for a maximum of 7 days (usually 3-5 days) secured with
clear adhesive dressing is safe practice. The sub-clavicular
and abdominal areas are suitable s.c. sites; easily acces-
sible and appropriate even if peripheral circulation is
diminished. Rescue or breakthrough immediate-release
medications should be prescribed s.c., sublingually (s.l.) or
rectally.34
In the last days of life, many patients are confused and
unable to express their needs. Thus, regular dosing or pre-
scribing orders, such as ‘offer, may refuse’, may be a better
option than ‘as needed’ or ‘per request’.
Recommendations
 In the absence of a central venous catheter, continuous
s.c. infusion is the preferred route, being effective,
feasible, safe and inexpensive [V, B].4 https://doi.org/10.1016/j.esmoop.2021.100225 In the last days of life, s.c. cannulae should be placed on
the trunk or abdomen, rather than extremities, due to
potentially diminished peripheral perfusion [V, B].
NUTRITION AND HYDRATION
In patients with an expected survival of less than a few
months and not receiving anticancer treatment, nutritional
interventions with low risks/burdens for the patient (coun-
selling, oral nutritional supplements) are preferred. Very few
trials compare different modes or amounts of nutritional
support. In a study randomising patients with severely
compromised food intake and limited survival of 1-4 months,
supplemental parenteral nutrition or oral feeding did not
improve QoL or survival, but increased adverse events.35
Therefore, patients with expected survival of days-to-
weeks are unlikely to benefit from enteral and parenteral
artificial nutrition.36,37 Each individually focused decision
requires intensive clinical and ethical consideration and
discussion.38 Before considering use of artificial nutrition,
therapeutic goals should be explicit.
If the patient is able to swallow, they should be
encouraged to take liquids and preferred foods by mouth,
using small-volume meals spaced throughout the day or at
request of the patient rather than large quantities of food
at scheduled times. For patients in the last weeks of life
nutritional interventions are rarely indicated, and care
needs to primarily target alleviation of hunger (if present),
thirst and other distressing symptoms.36,37
Pharmaceutical agents to stimulate appetite are few and
limited by lack of evidence of efficacy. A short trial of pro-
gesterone analogues or corticosteroids may be considered
depending on treatment goals and individual riskebenefit
analysis.37
Nutrition, however, may be less important when
approaching the last weeks and days of life, as reduced
intake of food and liquids caused by anorexiaecachexia,
dysphagia, delirium and reduced desire for food is part of
a natural process of dying.
Concerns about whether the patient’s impending death is
due to starvation or if it is possible to stimulate patient
desire to eat with or without pharmacological treatments
and artificial feeding tubes should be explored. Family
members and caregivers often experience a high level of
distress when food and fluids are no longer taken orally. The
decision to hydrate cancer patients by i.v. or s.c. adminis-
tration at EoL remains controversial.39 Artificial hydration
given through i.v. or s.c. routes in the last days of life has
not been demonstrated to prevent or relieve symptoms of
thirst, dehydration or delirium in randomised trials.40
Moreover, hydration may worsen oedema, ascites and res-
piratory secretions. For these reasons each clinical case
must be carefully evaluated and hydration tailored accord-
ing to patient needs. Impeccable mouth care should always
be provided.
Recommendations
 In patients with an expected survival of less than a
few weeks or days, the invasiveness of nutritionalVolume 6 - Issue 4 - 2021
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V
interventions should be decreased and dietary coun
selling and oral supplements should be provided
[V, B].
 In patients with an expected survival of less than a few
weeks, comfort-directed care is the recommended
approach, including alleviating thirst, eating-related
distress and other debilitating symptoms [V, B].
 Artificial nutrition should not be initiated in the last
weeks of life [V, D].
 Artificial hydration does not improve or prevent symp-
toms of thirst [V, C].MEDICATION AND INTERVENTION REVIEW
Polypharmacy is common, but undesirable, at EoL.41 Phys-
iological changes such as impaired swallowing and wors-
ening renal or hepatic function affect medication
management. Continued therapy should be based on riske
benefit analysis of each medication for the specific patient
situation. Potential withdrawal symptoms and drugedrug
interactions should be considered. Tools have been devel-
oped to assist clinicians with discontinuing medications at
EoL.42
Preventive medications, e.g. lipid-lowering agents, anti-
platelet agents and proton pump inhibitors with limited
benefit at EoL should be discontinued.41 Antiseizure medi-
cations should be continued if the patient has a history of
seizures. S.c. benzodiazepines (e.g. midazolam or clonaze-
pam) offer an appropriate substitute. Diabetes medications
may be contraindicated due to impaired organ function and
decreased food intake. Blood glucose should be managed
to a target of 5-15 mmol/l to minimise symptoms.
Bisphosphonates or denosumab to prevent skeletal-related
events should not be initiated, and previously commenced
administration should be discontinued if life expectancy is
short.43 Zoledronic acid may be considered for alleviation of
delirium caused by malignant hypercalcaemia.44Anticoagulation
Therapeutic anticoagulation should be evaluated based on
riskebenefit analysis, where benefit may be diminished and
bleeding risks increased at EoL. Therefore, thrombopro-
phylaxis, generally recommended for hospitalised cancer
patients, may be inappropriate at EoL, when risk of major
bleeding is increased.45,46Antibiotics
Antibiotics may provide symptomatic benefit, especially for
urinary tract infection, less so for respiratory tract infection
or resolution of fever and minimal benefit for bacter-
aemia.47 Symptomatic benefit versus possible adverse ef-
fects should be considered.Blood transfusion
Anaemia, presenting as fatigue or dyspnoea, is common in
advanced cancer and often multifactorial. Red blood cellolume 6 - Issue 4 - 2021transfusion may provide short-term benefit and improve
QoL.48 Blood transfusion is not associated with improved
PS.48 Potential harms, though infrequent, include allergy,
haemolysis and fluid overload.
Platelet transfusion for thrombocytopaenia may assist
symptomatic bleeding although benefits are limited by the
short half-life of platelets.49 Other strategies utilised to
control bleeding include local measures and oral, i.v. or
topical fibrinolysis inhibitors (e.g. tranexamic acid).
The ESMO CPG on the management of anaemia and iron
deficiency in patients with cancer provides detailed rec-
ommendations for treatment of anaemia and iron defi-
ciency.50 Currently, there are no robust studies to guide
decision making.49 For this reason, therapy must be per-
sonalised according to expected symptomatic benefit, riske
benefit assessment and the patient’s hopes.Recommendations
 Prophylactic anticoagulation should not be used at EoL
[IV, D].
 Red blood cell and platelet transfusions may have limited
benefits in the last weeks of life [IV, D].SYMPTOM MANAGEMENT
Cancer-related fatigue
Cancer-related fatigue (CRF) is defined as a distressing,
persistent, subjective sense of physical, emotional and/or
cognitive tiredness or exhaustion, related to cancer or
cancer treatment and disproportionate to recent activity,
that interferes with usual functioning.51
The intensity of CRF increases in the last months of life,
with a prevalence of 88% in the last 1-2 weeks of life52 and
up to 98% during the last days of life.53 The detailed prin-
ciples of diagnosis and management of CRF (not considering
specifically EoL) are reported in a recently published ESMO
CPG.51
Most pharmacological treatments are not recommended
in CRF, except short-term use of dexamethasone or meth-
ylprednisolone.51 The use of corticosteroids is contra-
indicated in patients with delirium or approaching
imminent death.44Pain
As indicated in an existing ESMO CPG, pain is reported in
30%-75% of patients in the last days of life.34 Although
prevalence and average intensity of pain often decreases in
the last days of life, some patients may experience signifi-
cant pain exacerbations.54
Assessment of pain should be carried out regularly and
consistently and should refer to the quality and intensity,
pathophysiology, trigger and relieving factors, concomitant
symptoms, efficacy and tolerability of analgesics currently
and previously used, clinical situation, impact on patient
daily functioning, pain-related psychosocial and spiritual
distress, alcohol or substance abuse and patient needs.34https://doi.org/10.1016/j.esmoop.2021.100225 5
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visual analogue scale (VAS), verbal rating scale (VRS), nu-
merical rating scale (NRS) and observational scales based on
clinical assessment in the presence of lowered conscious-
ness, delirium or palliative sedation should be used.55
Principles of treatment. As death approaches, ongoing pain
management is usually required, with morphine and other
opioids being the mainstay of treatment.34 Non-
pharmacological management that promotes comfort
measures and psychological support may be beneficial.
Reversible causes of pain should be considered e.g. uri-
nary retention, a common cause of pain and agitation in the
last days of life.
Choice of medication. The process of dying includes pro-
gressive renal failure with oliguria and anuria. Opioids and
their metabolites, excreted renally, may accumulate,
causing confusion, drowsiness and hallucinations. Careful
review of continuing need should be made, and reduced
doses or extended dosing intervals considered.34 Fentanyl
and methadone have inactive metabolites and only small
amounts of unaltered drug are excreted renally. Buprenor-
phine has a dual route of elimination. Dose modification is
not required.
If a pain crisis occurs in the last few days of life,
immediate-release s.l., s.c. or i.v. opioids ensure faster pain
control.34
The fear of opioid toxicity or hastening death may affect
use of opioids in the last days or hours of life.56 The medical
use of opioids may be associated with a shortened survival
in advanced cancer patients, but cause and effect rela-
tionship remains uncertain and decisions should be guided
by goals of care, patient prognosis and riskebenefit
assessment of the treating physician.57,58
There is only low-level evidence to guide use of nonste-
roidal anti-inflammatory drugs (NSAIDs) in the last weeks of
life.59
Other orally administered adjuvant drugs, e.g. gaba-
pentin, pregabalin or serotonin-norepinephrine re-uptake
inhibitors, should be withdrawn. Early and gradual weaning
of these medications prevents a withdrawal syndrome.Nausea and vomiting
At EoL, possible causes of nausea and vomiting (NV)
include: emetogenic medications (e.g. opioids), recent ChT
or RT, psychological causes (anxiety, fear), biochemical
causes (e.g. hypercalcaemia, hyponatraemia, uraemia,
raised creatinine), increased intracranial pressure, vestibular
dysfunction, excessive cough, ascites, gastroparesis and
malignant bowel obstruction.60
Treating potentially reversible causes of NV should be
considered in the context of prognosis and patient goals.
Appropriate hydration and correction of electrolyte abnor-
malities should be considered in patients with NV.
Largely poor quality or uncontrolled trials and case
studies are available to guide clinical prescribing judgement.
The level of evidence in most studies is low. Antiemetic6 https://doi.org/10.1016/j.esmoop.2021.100225therapy is tailored to potential mechanism of action,
although empirical therapy is effective.60 The drug of choice
for managing NV in advanced cancer is metoclopramide
titrated to effect. Alternative options include haloperidol,
levomepromazine or olanzapine. For opioid-induced NV, no
recommendation can be made.60
Evidence supports switching opioid, or administration
route from oral to s.c. to reduce opioid-induced NV.61 Ac-
cording to the 2016 updated Multinational Association of
Supportive Care in Cancer (MASCC)/ESMO consensus rec-
ommendations,60 weak evidence suggests drugs with an
antidopaminergic mode of action (e.g. haloperidol, meto-
clopramide) and serotonin 5-hydroxytryptamine (5-HT3)
receptor antagonists (e.g. ondansetron, palonosetron) are
effective in patients with opioid-induced emesis.34,60 The
evidence for effectiveness of cannabinoids in treatment of
non-ChT-associated NV is too weak to recommend its use in
the last days of life.62
According to the 2016 updated MASCC/ESMO consensus
recommendations, the drug recommended in malignant
bowel obstruction is octreotide, with or without an anti-
emetic such as haloperidol.60 For NV associated with ma-
lignant bowel obstruction, continuous nasogastric suction is
an uncomfortable intervention and is suggested only as a
short-term option.Breathlessness
Breathlessness is the most distressing symptom in cancer
patients at any stage of disease. It is highly prevalent,
affecting between 20% and 70% of cancer patients and is
associated with poor prognosis.63 The evaluation of
breathlessness should identify all contributing causes that
are amenable to treatment. The gold standard for breath-
lessness assessment is based on patient self-report at rest
and on moving.63 In patients unable to self-report breath-
lessness, vital signs may assist diagnosis and treatment.
Screening for breathlessness should include an assessment
of intensity with unidimensional tools (e.g. NRS) and func-
tional impact [e.g. modified Medical Research Council
(mMRC) breathlessness scale].63
Principles of treatment. For dyspnoea, the initial focus
should be on optimising treatment of a patient’s underlying
disease.63,64 Treating potentially reversible causes should be
considered. Non-pharmacological treatment could provide
short-term benefit but at EoL this may not be tolerated.63
Choice of medication. Most of the evidence comes from
studies in chronic obstructive pulmonary disease (COPD)
patients. According to the ESMO CPG on breathlessness,
preferred treatment of the relief of chronic refractory
breathlessness is a systemic, oral or parenteral low-dose
opioid that reduces mean chronic breathlessness by
w20% over baseline with no evidence of significant or
clinically-relevant respiratory adverse effects.63
In opioid-tolerant patients, an increase in baseline dose
of opioid by 25%-50% may be considered.63 A larger
confirmatory randomised trial is currently under way toVolume 6 - Issue 4 - 2021
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cancer patients (clinicaltrials.gov NCT03367156).63 Benzo-
diazepines are frequently used when breathlessness is
associated with anxiety. There is insufficient evidence from
clinical trials to support benzodiazepine use for the relief of
breathlessness. In individuals suffering from refractory
breathlessness, midazolam infusion may be considered as
palliative sedation. Randomised, controlled studies with
antidepressants have not reported significant improvement
of breathlessness. Three case studies reported breathless-
ness relief by citalopram, sertraline or mirtazapine.63 Sup-
plemental oxygen is indicated only in patients with chronic
severe hypoxaemia.63Noisy breathing
In the last hours of life, accumulation of tracheobronchial
secretions, caused by a decreased ability to swallow and
reduced reflexive clearing of the oropharynx, may occur as a
result of weakness and decreased neurological function.
This leads to noisy breathing (NB), gurgling, crackling or
rattling sounds with each breath, often referred to as ‘death
rattles’.65
NB is relatively common in dying patients. It is an indi-
cator of impending death and present in 12%-80% of pa-
tients in last 3 days of life.26,66 The median time of onset is
11-28 hours before death67 and is more frequent in women
and weakly associated with lung and brain metastases.65,66
Anticipatory clarification of its nature and meaning
should be a key element of EoL care. NB is not associated
with dyspnoea. Patients are usually unconscious when it
occurs. It is unlikely to cause suffering or be bothersome to
the patient, although highly distressing for relatives and
those in close vicinity. It may be perceived as indicating
untreated dyspnoea, drowning or suffocation.26,66,67
The accumulation of tracheobronchial secretions may be
reduced by avoiding fluid overload.67,68 Evidence does not
support oropharyngeal suction, which may even exacerbate
secretions.67 Most family caregivers report suctioning in-
creases patient discomfort and does not bring lasting
improvement. Changing patient position, e.g. head down or
lateral, may help but has not been studied for
effectiveness.67
Commonly used medications for reducing tracheobron-
chial secretion, thereby reducing the sound of NB, include
hyoscine butylbromide and glycopyrronium bromide, which
both weakly cross the bloodebrain barrier. Less preferred
are hyoscine hydrobromide and atropine, which do cross
the barrier. The use of antisecretory medication is contro-
versial and not recommended by the National Institute for
Health and Care Excellence (NICE)69 with little evidence to
inform clinical practice.67
Antimuscarinic agents may induce dry mouth, urinary
retention, delirium, agitation or excessive sedation and
require regular monitoring for side-effects.70 If unaccept-
able side-effects persist, antimuscarinic agents should be
stopped. If NB continues, changing or ceasing pharmaco-
logical interventions should be considered.Volume 6 - Issue 4 - 2021Nursing interventions are very important not only to
manage NB, but also to communicate with the family,
clarifying the patient’s lack of awareness of the symptom
and fostering the family’s ability to remain with the patient,
thereby reducing their distress.26,67
Delirium
Delirium has an adverse impact on functional decline,
increased length of hospital stay and medical cost, is a
significant cause of distress and is associated with short
survival. In the last days of life w90% of patients suffer
from delirium.44 Delirium is characterised by disturbed
consciousness with reduced ability to focus, sustain or shift
attention, altered cognition or perceptual disturbance and
acute onset that occurs over a short period of time and
fluctuates throughout the day.71
Non-pharmacological interventions that target delirium
risk factors have been recommended for preventing and
managing the condition in various CPGs, including guidance
for care of inpatients in hospitals.44
Patient reports suggest the presence of family caregivers
is beneficial, helps orientate confused patients and protects
against fear, anxiety and isolation. Diagnostic tools, phar-
macological and non-pharmacological management of
delirium in advanced cancer patients is the subject of a
recent ESMO CPG.44
Intractable symptom management and palliative sedation
Palliative sedation is considered a treatment of last resort
for EoL symptoms refractory to standard therapies and
where a patient remains distressed despite all attempts at
symptom relief.33 Frequency of palliative sedation varies
widely between studies from 10% to 50%. This may be due
to inconsistency of definitions and variations in local prac-
tice.72 The most frequent symptoms for which sedation is
used are refractory delirium, dyspnoea, psychological
distress and pain.73 Emergency situations, e.g. catastrophic
haemorrhage, convulsions or airway obstruction, may also
require rapid sedation to relieve distress. Refractory
symptoms are defined when the only available treatment
options would (i) not adequately relieve distress, (ii) not
provide relief in an appropriate time frame or (iii) be
associated with intolerable toxicity or adverse effects.33
Ideally, sedation is only considered after PC consultation
and other multidisciplinary input where appropriate and
available (e.g. pain specialist, psychiatrist). The decision
must be made in discussion with the patient or legal sub-
stitute decision-maker if the patient is unable to consent.
The consent process must include discussion of alternatives
to sedation for symptom relief, the aim and process of
sedation and predicted prognosis.33
The intent of therapy is to reduce consciousness and
relieve the distress. Ethically, this intention separates the
practice from euthanasia or medically-assisted dying in that
treatment is proportionate and the intention is reduced
consciousness, not death.74 Sedation medication doses are
titrated only until required depth of sedation is achieved.https://doi.org/10.1016/j.esmoop.2021.100225 7
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sedation has not been associated with reduced survival in
cohort studies in PC settings.73
Medications used for sedation are usually continuous
infusions (s.c. or i.v.) of benzodiazepines (midazolam, lor-
azepam), antipsychotics (levomepromazine, chlorproma-
zine) or barbiturates (phenobarbitone) and less commonly
anaesthetic agents (propofol).33,75 Other medications for
symptom management (e.g. opioid analgesia) are usually
continued during sedation, especially if they have been
effective. Sedation for existential or spiritual distress re-
mains controversial, as is use of sedation where expected
prognosis is >2 weeks.74 In some situations, respite
sedation is considered, i.e. the patient is temporarily
sedated then awoken after a period of respite from their
distress.74
Use of sedation can have emotional impacts on both
families and staff and must be considered. Regular
communication must be maintained with family and sup-
port persons involved, providing information and reassur-
ance regarding the patient’s comfort and expected
prognosis.76 Sedation removes the ability to finalise con-
versations, goodbyes and last wishes with families. Oppor-
tunity should be provided for conversations before sedation
is initiated.
To ensure consistency of practice and ethical application,
local protocols should be developed, followed and
audited.33,73Recommendations
 The intensity of pain should be assessed regularly,
particularly using validated instruments to include
patients with reduced consciousness or cognition [V, C].
 Pain treatment should be personalised and monitored
also in the last days of life [V, B].
 Non-oral routes of administration should be used, such
as s.c. or i.v., whenever benefits outweigh burden [V, C].
 Concern about hastening death should not influence de-
cisions regarding opioid therapy [IV, B].
 The antiemetic drug of choice in advanced cancer is
metoclopramide titrated to effect [III, B].
 Alternative antiemetic options include haloperidol, levo-
mepromazine or olanzapine [V, C].
 There is limited evidence to guide antiemetic use of
cyclizine or 5-HT3 receptor antagonists [V, C].
 Metoclopramide should be used with caution in partial
bowel obstruction [V, C].
 Metoclopramide should not be used in complete bowel
obstruction [V, D].
 Octreotide and haloperidol are recommended for NV in
malignant bowel obstruction [II, A].
 Treatment with regular, low-dose, slow release (SR) opi-
oids is recommended for palliating severe chronic
breathlessness in advanced disease [II, B].8 https://doi.org/10.1016/j.esmoop.2021.100225 In opioid-naive patients, starting daily dose of morphine
SR 10-20 mg orally over 24 hours can be used for relief of
cancer-related breathlessness [II, B].
 In opioid-tolerant patients, an increase in baseline dose
of opioid by 25%-50% may be considered for the relief
of cancer-related breathlessness [V, C].
 Corticosteroids may be considered for palliation of
cancer-related breathlessness refractory to other treat-
ments [II, C].
 Benzodiazepines may be used with caution in cancer pa-
tients for relief of breathlessness with associated anxiety
if opioids are not effective [V, C].
 In the last days of life, benzodiazepines may be consid-
ered for palliative sedation in patients with refractory
breathlessness despite other treatments [IV, C].
 The use of antidepressants for treatment of breathless-
ness should be limited to clinical trial contexts [V, C].
 Palliative oxygen is not recommended in patients with
resting SpO2 90% [II, D].
 The risk of NB may be reduced by avoiding fluid overload
[V, B].
 Repositioning of the patient may enable elimination of
oropharyngeal secretions [V, B].
 There is no evidence to support the use of anticholin-
ergic medications for NB [V, C].
 Oropharyngeal suction should not be used for NB [V, D].
 Clear communication with the patient’s family about the
cause and nature of NB is vital [V, B].
 The evidence is insufficient to recommend routine use of
screening tools in making a diagnosis of delirium in can-
cer patients [III, C].
 Deprescribing is worthwhile in older patients, although
there is insufficient data to support this recommenda-
tion for all cancer patients from the specific perspective
of delirium prevention [V, B].
 Administration of olanzapine may offer benefit in symp-
tomatic management of delirium [III, C].
 Administration of quetiapine may offer benefit in symp-
tomatic management of delirium [V, C].
 Benzodiazepines are effective at providing sedation and
potentially anxiolysis in acute management of severe
symptomatic distress associated with delirium [II, C].
 Sedation is considered as a treatment of last resort
where symptoms are refractory to available treatment
[V, C].PSYCHOLOGICAL ISSUES
Assessment of social and emotional factors, mood, anxiety
and depression are part of the comprehensive assessment
of cancer patients’ suffering. The presence of emotional
distress and generalised psychological symptoms is com-
mon, with mood disorders ranging between 30% and 40%
of patients at EoL.77 Patients with pre-existing psychiatric
disorders are likely to require more support and assistance.
It is important to screen for exacerbation of pre-existingVolume 6 - Issue 4 - 2021
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terventions in the last days and weeks of life may be
difficult.Management
The therapeutic relationship of the treating physician with
the patient and family is important in managing psycho-
logical conditions. To ensure good patient-centred care,
emotional and psychosocial factors should be considered
alongside physical symptoms and outcomes.77
Non-pharmacological measures. As EoL approaches, cancer
patients may not have the cognitive ability or energy to
participate in many types of interventions, leaving life re-
view, relaxation therapies and more general supportive and
pharmacological therapies as the only interventions.77
Strategies to enhance a sense of meaning can assist with
supporting dying cancer patients.
Pharmacological measures. Without early and compre-
hensive assessment, pharmacological interventions may not
have sufficient time to provide real benefit. This is partic-
ularly true for antidepressant medication.78 Anxiety is often
better managed with antidepressant medications initially
rather than benzodiazepines. However, at EoL, anxiety and
stress-related disorders, insomnia, terminal agitation and
restlessness are more likely to respond to benzodiaze-
pines.33,63 Resistant anxiety and depression and severe
sleep disturbances may benefit from the use of antipsy-
chotics.79 Use of palliative sedation should be considered in
these patients at EoL.33Recommendations
 Assessment and treatment of anxiety and existential
distress should be undertaken early in the disease as
these are highly prevalent in cancer patients at EoL [I, A].
 Early detection and treatment of psychological distress
leads to better adherence to treatment, better commu-
nication, reduced patient anxiety and reduced depres-
sion [II, A].SPIRITUAL DISTRESS
In 2014, the World Health Assembly passed a resolution
which included spiritual care as an essential domain of PC. It
was noted in the definition “that it is the ethical duty of
health care professionals to alleviate pain and suffering,
whether physical, psychosocial or spiritual.”80 Many inter-
national guidelines have been developed for addressing
spiritual care as part of whole person care.11,81-84 Spiritu-
ality should be addressed as part of well-being and the
identification of spiritual distress as part of symptom
management. Spirituality is defined broadly as a “dynamic
and intrinsic aspect of humanity through which persons
seek ultimate meaning, purpose, and transcendence and
experience relationship to self, family, others, community,
society, nature and the significant or sacred”, withVolume 6 - Issue 4 - 2021spirituality being “expressed through beliefs, values, tradi-
tions and practices”.11
QoL for patients with cancer has been shown to
encompass the spiritual as well as physical and psychosocial
domains of care, with spiritual well-being as significant as
physical well-being. A diagnosis of cancer raises spirituality-
related questions and concerns, both existential and reli-
gious particularly for a person diagnosed with cancer and at
transitions such as end of active treatment.85 Having a
strong sense of spirituality helps patients to adjust to and
cope with illness.
Spirituality may affect how a patient may cope with the
cancer experience and find meaning and peace, and may
assist in finding a sense of health in the midst of disease.
Spirituality has been demonstrated to impact health out-
comes including pain, pain interference, pain catastrophising
and QoL and has been associated with decreased mortality
and morbidity.86,87 Studies also demonstrate that spiritual
well-being in cancer patients has been associated with lower
levels of depression, better QoL near death, protection
against EoL despair and desire for a hastened death.11,86
The incidence of spiritual distress is high in cancer pa-
tients; 73% of cancer patients expressed at least one spir-
itual need and up to 40% with newly-diagnosed and
recurrent cancer reported a significant level of spiritual
distress.88 Untreated spiritual suffering may worsen pain
experience,89 may be of greater concern than physical
symptoms and lead to increased health service utilisation.90
Identifying spiritual distress can have important implica-
tions for health outcomes including improved QoL for
patients.
Spiritual distress may extend along the continuum of care
from ‘common, normal feelings of vulnerability, sadness and
fear, to problems that become disabling such as depression,
anxiety, panic, social isolation and existential spiritual cri-
ses’.89 Spirituality should be an integral component of
cancer care, with the recommendation for routine spiritual
assessments.91 The National Cancer Comprehensive
Network has developed a spiritual distress diagnosis table
(Supplementary Table S1, available at https://doi.org/10.
1016/j.esmoop.2021.100225).92 Spiritual, religious and
existential aspects of care have been identified as one of
eight required domains of quality palliative and hospice
care.93
Tools for assessing spiritual distress and spiritual concerns
include the Faith, belief, meaning, importance and influ-
ence, community, address/assessment and plan (FICA) tool,
which was validated for cancer patients (Supplementary
Table S2, available at https://doi.org/10.1016/j.esmoop.
2021.100225).82 A spiritual history should be asked in the
context of personal or social history. Spiritual distress and/
or spiritual resources should be documented as part of the
assessment and plan for each patient.
The practice of spiritual care is based on a generalist-
specialist model of care; health care providers address
spiritual concerns and work with spiritual care specialists,
such as trained chaplains, in treating spiritual distress.11
Thus, all clinicians should address patients’ spirituality,https://doi.org/10.1016/j.esmoop.2021.100225 9
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resources of strength.
Clinicians can respond to a patient’s sharing of spiritual
distress by compassionate listening, offering presence and
by sharing a sacred moment. Clinicians should consider
referral to spiritual care professionals, such as chaplains,
and therapies such as mindfulness, art and narrative94 or
music therapy. If available, meaning-oriented therapy,95 and
dignity therapy96 are options for care. In-depth spiritual
counselling and exploration should be referred to trained
spiritual care professionals.92Recommendations
 Spiritual distress should be assessed as part of routine
cancer care [V, A].
 Clinicians can use compassionate listening skills to be
present to patients’ suffering and help assess and
address spiritual distress [V, C].
 Interventions for spiritual distress include referral to spir-
itual care professionals, mindfulness, art, narrative and
music therapy, meaning-oriented therapy and dignity
therapy [II, A].
 For in-depth spiritual assessment and counselling,
referral should be to a trained chaplain or spiritual
care professional [V, A].BEREAVEMENT CARE
Bereavement care begins before death of the patient.
Bereavement is a universal experience, with grief a normal
response to loss. It is a multilayered construct with
emotional, physical, cognitive, spiritual and behavioural
aspects and responses that vary among those who grieve.Responses to loss
Most people are resilient and manage changes brought
about by the death of a loved one and adjust to loss with
the help of family and friends.97-99 Some will experience a
more intense response to loss but adjust within a reason-
able time frame, without the need for intervention other
than mutual group and/or structured support.100 A small
proportion of bereaved individuals experience a compli-
cated grief or prolonged grief disorder and benefit from
additional support.101,102 Early identification, before death,
of individuals who may need professional help in the future
is important, as efficacy of post-death outreach services is
not proven.13,102Assessment of bereavement need
There is currently no single agreed tool to assess for
bereavement risk before death.103 Reviews conclude that
factors influencing vulnerability to poor outcomes, in terms
of complicated grief and post-loss depressive symptoms,104
are: loss of a child, spousal loss at a young age, history of
previous multiple losses and life struggles, lack of pre-
paredness for the loss, high levels of caregiver burden pre-10 https://doi.org/10.1016/j.esmoop.2021.100225death, high levels of pre-death distress and depressive
symptoms,13 high levels of family conflict,105 financial
distress and poverty12,106 and lower levels of educational
attainment.12,106
Treatment-related factors, such as aggressive medical
interventions, ambivalence regarding treatment and family
conflict regarding treatment may predispose family mem-
bers to poor outcome in bereavement.107
Risk factors alone are unhelpful in assessment of need as
an individual’s coping ability influences outcomes.108,109
Factors that may indicate resilience in people facing loss
are connection to family and community, access to practical
support, previous experience of coping with loss, accep-
tance of death, engagement with spiritual beliefs and rit-
uals, ability to make meaning in relation to their experience
of loss and high levels of personal resources.110Resources and services for families
Routine referral for bereavement support is not indicated.
Evidence-informed information on grief may assist in-
dividuals and families to normalise grief. For the majority,
this will be the primary intervention. It is important to
signpost appropriate services if family members self-identify
a need. A tiered approach to bereavement care,99,101 which
requires knowledge of and linkages to local services and
referral protocols, may be a useful intervention.
Information about grief and bereavement and available
support services should be provided through accessible
written material including braille, websites, telephone help
lines, information events or face-to-face contact with
members of the PC team, being aware of culture, faith and
language.Improved outcomes with carer support
A proactive approach may be necessary with carers who
have provided care over a prolonged period or who
demonstrate high levels of pre-death distress, depressive
symptoms or report a history of multiple losses. These
factors have been associated with poor outcome in
bereavement.12,111 Tools recommended for screening for
psychosocial distress are the Distress Thermometer and
General Health Questionnaire.89,112 Referral for screening
and assessment by psycho-oncology services or other
appropriate disciplines or external agencies should be
considered for family members/carers where there are
concerns about the possibility of poor outcome in
bereavement.Recommendations
 Clinicians should have processes in place to carry out
initial screening for psychosocial distress among carers/
family members in the pre-death phase [IV, B].
 Referral for intervention and support to psycho-
oncology, social work, spiritual care or other appropriate
disciplines should be considered for carers with a history
of prolonged caring, as they are vulnerable to anxiety,Volume 6 - Issue 4 - 2021
G. B. Crawford et al. ESMO Opendepression and social and financial distress before and
after death [III, B].
 Staff need education about grief and loss in order to
recognise background factors in carers that may pre-
dispose some to poor outcome in bereavement [V, C].
 Assess for pre-death dissatisfaction or conflict about the
nature or direction of care or lack of preparedness for
death among family members and use targeted commu-
nication strategies to address concerns [IV, C].
 Information about normal and adverse grief trajectories
and about routes of access to appropriate levels of sup-
port should be made available to all families to facilitate
help-seeking after death [IV, C].
 Information about, and referral to, specialist services of-
fering evidence-informed interventions are priorities for
those who are potentially at risk of complicated or pro-
longed grief disorder [III, B].
 Teams should review the death from the family perspec-
tive and if there were any unexpected difficulties a team
member should contact the family in the post-death
period [V, C].
METHODOLOGY
This CPG was developed in accordance with the ESMO
standard operating procedures for Clinical Practice Guide-
lines development (http://www.esmo.org/Guidelines/
ESMO-Guidelines-Methodology). The relevant literature
has been selected by the expert authors. Levels of evidence
and grades of recommendation have been applied using the
system shown in Supplementary Table S3, available at
https://doi.org/10.1016/j.esmoop.2021.100225.113 State-
ments without grading were considered justified standard
clinical practice by the experts and the ESMO Faculty. This
manuscript has been subjected to an anonymous peer
review process.
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